✨ Free AI Report
Verve Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Verve Therapeutics, Inc.
Company Research

Verve Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Verve Therapeutics was a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease. The company specialized in in vivo base editing technology targeting genetic drivers of disease, w...

Analyst-debate audio for Verve Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Verve Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Early-stage gene-editing biotech with strong scientific promise but significant execution risk and regulatory uncertainty in...

Read the full analyst-debate transcript →
Industry Gene Therapy
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Verve Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Verve Therapeutics, Inc. Overview

Pro stress-test →

Verve Therapeutics was a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease. The company specialized in in vivo base editing technology targeting genetic drivers of disease, with its lead program VERVE-102 addressing PCSK9 for cholesterol management.

Strategic Profile

Pro stress-test →

Verve focused on breakthrough gene-editing approaches to cardiovascular disease rather than traditional pharma models, positioning itself at the frontier of genetic medicine. The company achieved key regulatory milestones, receiving FDA Fast Track designation for VERVE-102 in April 2025, before its acquisition by Eli Lilly.

Competitive Landscape

Pro stress-test →

Verve competed in the genetic medicine space against companies like Beam Therapeutics, Prime Medicine, and CRISPR Therapeutics, which also pursue gene-editing approaches. Traditional cardiovascular pharma (Amgen, Regeneron) dominates the PCSK9 inhibitor market with established drugs, making Verve's in vivo approach a potential disruptor if successfully developed.

Industry Context

Verve Therapeutics, Inc. operates in Gene Therapy.

Key facts

Founded: 2018 · Headquarters: Cambridge, US · Employees: 274 · Revenue: N/A · Market cap: ~$0.99B (at acquisition)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Verve Therapeutics, Inc..

  • Achieved FDA Fast Track designation for VERVE-102 in April 2025, signaling regulatory confidence in the lead program
  • Projected net loss of $2.38 per share for 2025, with no revenue generation and early-stage pipeline
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025VERVE-102 received FDA Fast Track designation for PCSK9 targeting cardiovascular disease
  • July 2025Acquisition by Eli Lilly and Company completed; stock delisted from Nasdaq
  • +1 moreTrack every material event for Verve Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Verve Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CRISPRGene-editing therapeutics using CRISPR technology→BeamPrecision genetic medicines via base editing→Prime MedicinePrime editing platform for genetic medicine→RepathaPCSK9 inhibitor for cardiovascular disease→

Compare Verve Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Verve Therapeutics, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Verve Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Verve Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Verve Therapeutics, Inc. do this quarter?”
“Is Verve Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Verve Therapeutics, Inc. do?+
Verve Therapeutics was a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease. The company specialized in in vivo base editing technology targeting genetic drivers of disease, w...
What is Verve Therapeutics, Inc.'s Cyborg Score?+
Verve Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Verve Therapeutics, Inc.'s main competitors?+
Named competitors include CRISPR, Beam, Prime Medicine, Repatha. The full competitive landscape is in the AskCyborg report.
How can I get the full Verve Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Verve Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Verve Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.